NASDAQ: PGENPrecigen Inc Stock Ownership - Who owns Precigen?
Insider buying vs selling
Have Precigen Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Harry Thomasian Jr. | Chief Financial Officer | 2025-05-16 | 51,441 | $1.45 | $74.59kSell |
| Phil Tennant | Chief Commercial Officer | 2025-05-16 | 22,969 | $1.45 | $33.31kSell |
| Donald P. Lehr | Chief Legal Officer | 2025-05-16 | 55,101 | $1.45 | $79.90kSell |
| Rutul R. Shah | Chief Operating Officer | 2025-05-16 | 58,096 | $1.45 | $84.24kSell |
| Helen Sabzevari | President and CEO | 2025-05-16 | 521,224 | $1.45 | $755.77kSell |
| Jeffrey B. Kindler | Director | 2025-03-13 | 39,655 | $1.74 | $69.00kBuy |
| Randal J. Kirk | Director | 2025-03-13 | 57,471 | $1.74 | $100.00kBuy |
| James S. Turley | Director | 2025-03-13 | 35,919 | $1.74 | $62.50kBuy |
| Cesar L. Alvarez | Director | 2025-03-13 | 35,919 | $1.74 | $62.50kBuy |
| Steven Frank | Director | 2025-03-13 | 28,735 | $1.74 | $50.00kBuy |
PGEN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when PGEN insiders and whales buy or sell their stock.
PGEN Shareholders
What type of owners hold Precigen Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Randal J. Kirk | 81.40% | 240,270,361 | $439.69M | Insider |
| Trading Sa Ares | 6.99% | 20,647,152 | $37.78M | Insider |
| Patient Capital Management LLC | 5.89% | 17,372,301 | $31.79M | Institution |
| Adage Capital Partners GP LLC | 3.82% | 11,276,000 | $20.64M | Institution |
| Blackrock Inc | 3.64% | 10,752,215 | $19.68M | Institution |
| Vanguard Group Inc | 2.98% | 8,795,959 | $16.10M | Institution |
| Iridian Asset Management LLC | 1.55% | 4,585,809 | $8.39M | Institution |
| Geode Capital Management LLC | 1.18% | 3,479,602 | $6.37M | Institution |
| Helen Sabzevari | 1.12% | 3,317,022 | $6.07M | Insider |
| Parkman Healthcare Partners LLC | 1.08% | 3,191,343 | $5.84M | Institution |
PGEN vs Biotech Stocks
Precigen Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.